Strategies for Treating Acute Migraines and Identifying Triggers. Literature review
DOI:
https://doi.org/10.12775/JEHS.2024.69.49179Keywords
migraine, migraine triggers, triptans, migraine with auraAbstract
Introduction
Migraine, a prevalent neurological disorder affecting a substantial portion of the global population, poses a significant burden on individuals' overall quality of life. While the exact pathophysiological mechanisms underlying migraine headache attacks remain elusive, the involvement of trigeminal pathway activation is well-documented. A multitude of factors, collectively termed triggers, have been identified as capable of precipitating migraine episodes, ranging from dietary components to environmental stimuli such as bright lights and weather fluctuations. Migraine headaches typically manifest as throbbing pain localized predominantly on one side of the head and are often accompanied by a constellation of additional symptoms including photophobia, phonophobia, and nausea. The management of migraine involves a diverse array of therapeutic modalities tailored to the specific characteristics of the pain experienced. These may include the administration of non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol, triptans, and antiemetics, among others. This study endeavors to explore the most prevalent triggers implicated in migraine onset, as well as contemporary treatment strategies, with an emphasis on incorporating the latest research findings and therapeutic advancements in this evolving field.
Aim of the study
This review aims to identify symptoms, triggers of acute migraine and solutions in its treatment process, including latest developments.
Material and method
This article presents the current state of knowledge about acute migraine, triggers and treatment options in various scientific articles. Publications describing acute migraine attacks and treatments including the most recent reports in the field were reviewed using the PubMed platform. The search included the keywords ‘migraine, 'migraine triggers', 'triptans', 'migraine with aura'.
References
Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine? Brain Behav. 2018 Jun;8(6):e00950. doi: 10.1002/brb3.950. Epub 2018 May 2. PMID: 30106228; PMCID: PMC5991594.
Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: from pathophysiology to treatment. J Neurol. 2023 Jul;270(7):3654-3666. doi: 10.1007/s00415-023-11706-1. Epub 2023 Apr 8. PMID: 37029836; PMCID: PMC10267278.
Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019 Jan;25(2 Suppl):S23-S34. PMID: 30681821.
Sevivas H, Fresco P. Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res. 2022 Jun 4;27(1):86. doi: 10.1186/s40001-022-00716-w. PMID: 35659086; PMCID: PMC9167529.
Tardiolo G, Bramanti P, Mazzon E. Migraine: Experimental Models and Novel Therapeutic Approaches. Int J Mol Sci. 2019 Jun 15;20(12):2932. doi: 10.3390/ijms20122932. PMID: 31208068; PMCID: PMC6628212.
Peer Tfelt-Hansen (2020): Pharmacological strategies to treat attacks of episodic migraine in adults, Expert Opinion on Pharmacotherapy, DOI: 10.1080/14656566.2020.1828347
Ong JJY, De Felice M. Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action. Neurotherapeutics. 2018 Apr;15(2):274-290. doi: 10.1007/s13311-017-0592-1. Erratum in: Neurotherapeutics. 2018 Jan 8;: PMID: 29235068; PMCID: PMC5935632.
Kelman L. Pain characteristics of the acute migraine attack. Headache. 2006 Jun;46(6):942-53. doi: 10.1111/j.1526-4610.2006.00443.x. PMID: 16732840.
Migraine the Lancet David W Dodick Dodick DW. Migraine. Lancet. 2018 Mar 31;391(10127):1315-1330. doi: 10.1016/S0140-6736(18)30478-1. Epub 2018 Mar 6. PMID: 29523342.
Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J, Altman J, Goadsby PJ, Macrae A. Premonitory symptoms in migraine: an electronic diary study. Neurology. 2003 Mar 25;60(6):935-40. doi: 10.1212/01.wnl.0000052998.58526.a9. PMID: 12654956.
Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992 Aug;12(4):221-8; discussion 186. doi: 10.1046/j.1468-2982.1992.1204221.x. PMID: 1525797.
Aguilar-Shea AL, Membrilla Md JA, Diaz-de-Teran J. Migraine review for general practice. Aten Primaria. 2022 Feb;54(2):102208. doi: 10.1016/j.aprim.2021.102208. Epub 2021 Nov 16. PMID: 34798397; PMCID: PMC8605054.
Bose P, Karsan N, Goadsby PJ. The Migraine Postdrome. Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1023-1031. doi: 10.1212/CON.0000000000000626. PMID: 30074547.
Tzankova V, Becker WJ, Chan TLH. Diagnosis and acute management of migraine. CMAJ. 2023 Jan 30;195(4):E153-E158. doi: 10.1503/cmaj.211969. PMID: 36717129; PMCID: PMC9888545.
Tepper SJ. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache. 2018 Nov;58 Suppl 3:238-275. doi: 10.1111/head.13379. Epub 2018 Sep 22. PMID: 30242830.
Fukui PT, Gonçalves TR, Strabelli CG, Lucchino NM, Matos FC, Santos JP, Zukerman E, Zukerman-Guendler V, Mercante JP, Masruha MR, Vieira DS, Peres MF. Trigger factors in migraine patients. Arq Neuropsiquiatr. 2008 Sep;66(3A):494-9. doi: 10.1590/s0004-282x2008000400011. PMID: 18813707.
Hoffmann J, Recober A. Migraine and triggers: post hoc ergo propter hoc? Curr Pain Headache Rep. 2013 Oct;17(10):370. doi: 10.1007/s11916-013-0370-7. PMID: 23996725; PMCID: PMC3857910.
Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007 May;27(5):394-402. doi: 10.1111/j.1468-2982.2007.01303.x. Epub 2007 Mar 30. PMID: 17403039.
Haghdoost F, Togha M. Migraine management: Non-pharmacological points for patients and health care professionals. Open Med (Wars). 2022 Nov 23;17(1):1869-1882. doi: 10.1515/med-2022-0598. PMID: 36475060; PMCID: PMC9691984.
Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J. The metabolic face of migraine - from pathophysiology to treatment. Nat Rev Neurol. 2019 Nov;15(11):627-643. doi: 10.1038/s41582-019-0255-4. Epub 2019 Oct 4. PMID: 31586135.
Borkum JM. Migraine Triggers and Oxidative Stress: A Narrative Review and Synthesis. Headache. 2016 Jan;56(1):12-35. doi: 10.1111/head.12725. Epub 2015 Dec 7. PMID: 26639834.
Schoonman GG, Sándor PS, Agosti RM, Siccoli M, Bärtsch P, Ferrari MD, Baumgartner RW. Normobaric hypoxia and nitroglycerin as trigger factors for migraine. Cephalalgia. 2006 Jul;26(7):816-9. doi: 10.1111/j.1468-2982.2006.01112.x. PMID: 16776696.
Silva-Néto RP, Peres MF, Valença MM. Odorant substances that trigger headaches in migraine patients. Cephalalgia. 2014 Jan;34(1):14-21. doi: 10.1177/0333102413495969. Epub 2013 Jul 5. PMID: 23832131.
Bekkelund SI, Hindberg K, Bashari H, Godtliebsen F, Alstadhaug KB. Sun-induced migraine attacks in an Arctic population. Cephalalgia. 2011 Jul;31(9):992-8. doi: 10.1177/0333102411409071. Epub 2011 May 31. PMID: 21628439.
Raffaelli B, Do TP, Chaudhry BA, Ashina M, Amin FM, Ashina H. Menstrual migraine is caused by estrogen withdrawal: revisiting the evidence. J Headache Pain. 2023 Sep 21;24(1):131. doi: 10.1186/s10194-023-01664-4. PMID: 37730536; PMCID: PMC10512516.
Nappi RE, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C. Role of Estrogens in Menstrual Migraine. Cells. 2022 Apr 15;11(8):1355. doi: 10.3390/cells11081355. PMID: 35456034; PMCID: PMC9025552.
Sureda-Gibert P, Romero-Reyes M, Akerman S. Nitroglycerin as a model of migraine: Clinical and preclinical review. Neurobiol Pain. 2022 Sep 27;12:100105. doi: 10.1016/j.ynpai.2022.100105. PMID: 36974065; PMCID: PMC10039393.
Yang CP, Huang KT, Chang CM, Yang CC, Wang SJ. Acute Treatment of Migraine: What has Changed in Pharmacotherapies? Neurol India 2021;69:S25-42.
Ong JJY, De Felice M. Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action. Neurotherapeutics. 2018 Apr;15(2):274-290. doi: 10.1007/s13311-017-0592-1. Erratum in: Neurotherapeutics. 2018 Jan 8;: PMID: 29235068; PMCID: PMC5935632.
Mayans L, Walling A. Acute Migraine Headache: Treatment Strategies. Am Fam Physician. 2018 Feb 15;97(4):243-251. PMID: 29671521.
Becker WJ. Acute Migraine Treatment. Continuum (Minneap Minn). 2015 Aug;21(4 Headache):953-72. doi: 10.1212/CON.0000000000000192. PMID: 26252584.
Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S. How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine. Headache. 2016 Jul;56(7):1194-200. doi: 10.1111/head.12870. Epub 2016 Jun 20. PMID: 27322907.
Cady R, Martin V, Mauskop A, Rodgers A, Hustad CM, Ramsey KE, Skobieranda F. Efficacy of Rizatriptan 10 mg administered early in a migraine attack. Headache. 2006 Jun;46(6):914-24. doi: 10.1111/j.1526-4610.2006.00466.x. PMID: 16732837.
Najjar M, Hall T, Estupinan B. Metoclopramide for Acute Migraine Treatment in the Emergency Department: An Effective Alternative to Opioids. Cureus. 2017 Apr 20;9(4):e1181. doi: 10.7759/cureus.1181. PMID: 28533997; PMCID: PMC5438233.
Nowaczewska M, Wiciński M, Kaźmierczak W. The Ambiguous Role of Caffeine in Migraine Headache: From Trigger to Treatment. Nutrients. 2020 Jul 28;12(8):2259. doi: 10.3390/nu12082259. PMID: 32731623; PMCID: PMC7468766.
Derry CJ, Derry S, Moore RA. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database Syst Rev. 2014 Dec 11;2014(12):CD009281. doi: 10.1002/14651858.CD009281.pub3. PMID: 25502052; PMCID: PMC6485702.
Zarei M, Hajipoor Kashgsaray N, Asheghi M, Shahabifard H, Soleimanpour H. Non-opioid Intravenous Drugs for Pain Management in Patients Presenting with Acute Migraine Pain in the Emergency Department: A Comprehensive Literature Review. Anesth Pain Med. 2022 Nov 22;12(5):e132904. doi: 10.5812/aapm-132904. PMID: 36937180; PMCID: PMC10016134.
Goldstein J, Silberstein SD, Saper JR, Ryan RE Jr, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache. 2006 Mar;46(3):444-53. doi: 10.1111/j.1526-4610.2006.00376.x. PMID: 16618262.
Zobdeh F, Ben Kraiem A, Attwood MM, Chubarev VN, Tarasov VV, Schiöth HB, Mwinyi J. Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol. 2021 Dec;178(23):4588-4607. doi: 10.1111/bph.15657. Epub 2021 Sep 26. PMID: 34379793.
Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev. 2014 May 28;2014(5):CD009108. doi: 10.1002/14651858.CD009108.pub2. PMID: 24865446; PMCID: PMC6469574.
van Casteren DS, Kurth T, Danser AHJ, Terwindt GM, MaassenVanDenBrink A. Sex Differences in Response to Triptans: A Systematic Review and Meta-analysis. Neurology. 2021 Jan 26;96(4):162-170. doi: 10.1212/WNL.0000000000011216. Epub 2020 Nov 18. PMID: 33208542.
Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006 Nov;46 Suppl 4:S171-81. doi: 10.1111/j.1526-4610.2006.00601.x. PMID: 17078849.
Vila-Pueyo M, Page K, Murdock PR, Loraine HJ, Woodrooffe AJ, Johnson KW, Goadsby PJ, Holland PR. The selective 5-HT1F receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache. Br J Pharmacol. 2022 Feb;179(3):358-370. doi: 10.1111/bph.15699. Epub 2021 Nov 16. PMID: 34600443.
Puledda F, Younis S, Huessler EM, Haghdoost F, Lisicki M, Goadsby PJ, Tassorelli C. Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature. Cephalalgia. 2023 Mar;43(3):3331024231151419. doi: 10.1177/03331024231151419. PMID: 36786357.
Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23. PMID: 34160823.
Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022 Oct;62(9):1153-1163. doi: 10.1111/head.14389. Epub 2022 Oct 14. PMID: 36239038; PMCID: PMC9827820.
Blair HA. Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine. CNS Drugs. 2023 Mar;37(3):255-265. doi: 10.1007/s40263-023-00988-8. Epub 2023 Feb 4. Erratum in: CNS Drugs. 2023 Jul;37(7):661. PMID: 36739335; PMCID: PMC10299922.
Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022 Oct;62(9):1153-1163. doi: 10.1111/head.14389. Epub 2022 Oct 14. PMID: 36239038; PMCID: PMC9827820.
Ailani J, Nahas SJ, Friedman DI, Kunkel T. The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review. Pain Ther. 2023 Jun;12(3):655-669. doi: 10.1007/s40122-023-00501-5. Epub 2023 Apr 24. PMID: 37093356; PMCID: PMC10199993.
Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, Lin T, Silberstein SD. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache. 2019 Sep;59(8):1240-1252. doi: 10.1111/head.13551. Epub 2019 May 9. PMID: 31074005; PMCID: PMC6767146.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Zuzanna Kotowicz, Jakub Pabiś, Piotr Podgórski, Sandra Górecka, Miłosz Olszański, Aleksander Bogusz, Oskar Kwiatkowski, Anna Kołodziej, Anita Król
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 174
Number of citations: 0